Taking The Temperature of The Market

Presented By Savills

• 

  James Hicks

  Head of Real Estate & Leases

  Gilead

• 

  Michael Kyriakides

  Michael Kyriakides is an Investment Partner at Syncona, a life sciences investor focused on founding, building and funding companies. He works closely portfolio companies Freeline Therapeutics, Purespring Therapeutics and Clade Therapeutics. He is also a non-executive director of the board of Purespring Therapeutics and an observer to the board of Clade Therapeutics. Previously, Michael was a member of the Life Sciences team at L.E.K. Consulting and was involved in projects for pharmaceutical, biotech and private equity clients. Prior to joining L.E.K. Consulting, he was a clinical project and NMR manager in the Faculty of Medicine at Imperial College London. Michael obtained his doctorate degree in toxicology and metabolic profiling at Imperial College London.

  Syncona Investment Management Ltd

  Investment Partner

  Michael Kyriakides

  Investment Partner

  Syncona Investment Management Ltd

• 

  Katie Nelson

  Senior Asset Manager – UK & Ireland

  Kadans

• 

  Tom Mellows

  Tom has 25 years’ experience in commercial real estate and heads up Savills UK Science group. He specialises in advising science related occupiers needing R&D, lab and manufacturing space, as well as landlords and developers looking to deliver specialist science related space across the UK. Tom has advised on the acquisition of more than 600,000 sq ft of space over the last 3 years for the likes of Autolus, Quell Therapeutics, DNAe, Achilles Therapeutics, Avacta, Freeline Therapeutics and Omass.

  Savills

  Head of Savills Science UK

  Tom Mellows

  Head of Savills Science UK

  Savills

• 

  Tim Fry

  Tim leads the science business area, across the UKIMEA region for Arup. He leads on strategy and business development, maintains relationships with clients and manages a portfolio of projects. Tim is a chartered engineer and experienced team leader, having led multi-discipline teams in delivering engineering solutions on complex highly serviced buildings from concept design phases through to fully coordinated detail design and construction. He has been involved in science buildings from his first project over 28 years ago, working on the design and construction of a facility to produce injectable vaccines. As well as other manufacturing projects experience, Tim has been involved in the design of many research and development laboratories for a range of science users and scales of project. These have been for private clients, government institutes and higher education establishments. Tim thrives in solving client’s challenges bringing a wealth of experience to provide robust, energy efficient and sustainable design solutions, applying his knowledge of construction, commissioning and maintenance.

  ARUP UK

  Business Leader | Science UKIMEA

  Moderator

  Tim Fry

  Business Leader | Science UKIMEA

  ARUP UK

Construction And Development Pipeline: Addressing Supply Chain Uncertainty

Presented By Mace

• 

  Richard Surma

  Leading the UK R&D Estates Development function at AstraZeneca responsible for the development and execution of a Strategic Estates Masterplan. Responsible for the development of a capital masterplan which delivers the Strategic Estates Masterplan; ensure the identification, scoping, senior leadership review and decision making (capital approval/timing/delivery process) and progression of major R&D building projects required Responsible for the transition of any new capital projects into operational readiness, leading a world class Operational Readiness, transition and soft landings process

  AstraZeneca

  Head of Estate Development & Capital Programmes

  Richard Surma

  Head of Estate Development & Capital Programmes

  AstraZeneca

• 

  Anna Strongman

  Anna Strongman is CEO of Oxford University Development (OUD), a joint venture between Oxford University and Legal & General set up to build Innovation Districts and subsidised accommodation for graduate students and the university workforce. Anna was previously Managing Partner of Argent LLP in London, where she spent 12 years executing a range of asset, development, and business planning projects. Highlights included leading the Asset Management of King’s Cross, developing Coal Drops Yard, and setting up a BTR portfolio with JV partners Related. Anna was instrumental in building the business from 40 people to a team of 200 over a ten-year period and led the corporate side of the business as Managing Partner. Before joining Argent, Anna worked in the planning and economic development team of Arup, worked for DTZ in Scotland, and lived for 18 months in Japan, where she studied Japanese and conducted research at the Japan Productivity Centre as a Daiwa Scholar.

  Oxford University Development

  CEO

  Anna Strongman

  CEO

  Oxford University Development

• 

  Rob Partridge

  Rob is a Design Director at AKT II, responsible for leading a diverse range of projects, both in the UK and internationally, requiring a holistic focus across the many facets of design. Rob has led many of the practices most complex mixed use developments, with a keen motivation for the higher education and research sector, which has seen him lead some of the UK’s most notable research developments including the Francis Crick Institute, UCL East and Merck’s new European HQ at Belgrove House. Rob is a leading voice in how cities and buildings can accommodate future trends where the disciplines of life science, education and research combine with the already changing landscape of workplace design, to produce evolving innovation districts critical to the economic future of London and beyond.

  AKT II

  Design Director

  Rob Partridge

  Design Director

  AKT II

• 

  Robert Lemming

  As head of Mace’s Life Sciences Construction business, Rob leads on large-scale, award-winning projects including AstraZeneca’s global R&D Centre in Cambridge, St Bartholomew’s and London Hospitals and Jaguar Land Rover’s manufacturing capability. Most recently developers Oxford University and investor L&G appointed Rob to deliver two new buildings at Begbroke Science park. Rob works closely with multidisciplinary project teams and the science community to deliver pioneering facilities that enable clients to compete for the best researchers, scientists, and funding.

  Mace

  Director – Life Sciences & Pharma (Construction)

  Robert Lemming

  Director – Life Sciences & Pharma (Construction)

  Mace

• Moderator

  Matthew Soules

  Director

  Savills

Evolving Occupier Demands And Attracting Talent

Presented Stanhope, Imperial College, Cadillac Fairview

• 

  Réka Trón

  Reka is the cofounder and Chief Operating Officer of Multus. She has a background in Biological Sciences specialising in Synthetic Biology from Imperial College London. She is dedicated to making a positive impact in the world, which she combined with her interests in the different fields of Biology and cofounded Multus to unlock the cultivated meat industry through targeting the critical bottleneck of growth media.

  Multus

  Co-Founder and Chief Operating Officer

  Réka Trón

  Co-Founder and Chief Operating Officer

  Multus

• 

  Ivana Poparic

  Ivana Poparic is Head of Cluster Development at MedCity, an organisation representing London’s world-leading health and life sciences cluster and part of the London & Partners family. She leads a team supporting the development of new life sciences infrastructure to attract more inward investment and research into London region. Her team helps life sciences organisations to find right R&D and manufacturing spaces in London and works with developers, investors and local government to facilitate development of new life sciences spaces and city’s innovation districts. Ivana has extensive scientific and commercial expertise across the innovation pathway for drugs, devices, and digital technologies. Following a PhD in Human Genetics, her experience includes academic research, technology transfer, clinical research management, business development and investment roles.

  MedCity

  Head of Life Sciences Cluster Development

  Ivana Poparic

  Head of Life Sciences Cluster Development

  MedCity

• 

  Claire Dawe

  Claire joined Stanhope in September 2018 from Grosvenor Britain & Ireland where lead the Asset Management team for the Belgravia portfolio. There she was accountable for delivering the long term strategy to create distinctive and vibrant neighbourhoods which attract footfall, spend and offer prosperity to their tenants. Having moved around the Grosvenor business over ten years, and setting up the London Estate investment team, she has stakeholder management expertise, strategic planning experience, major change credentials and can point to significant operational success heading a £1bn business. Claire leads the Asset Management team at Stanhope, a portfolio of just under 3 million sq ft and £2.5bn of assets under management. Most notably, Claire has focused on the recently transformed White City area to deliver the strategic vision and further build on the areas commercial success and established reputation as a vibrant, innovative and creative part of London. Claire is a member of Real Estate Balance and a Mentor for Stanhope initiative Mentoring Circle.

  Stanhope

  Head of Asset Management

  Claire Dawe

  Head of Asset Management

  Stanhope

• 

  John Anderson

  John has played a key role in the evolution of the College's Financial Strategy since 2000 including the establishment of the College's Endowment Fund which now stands at just over half a billion pounds including the development of the Non-Core property portfolio (£8m in 2005 to £130m+ in 2022). The strategic objective is to maintain a viable financial strategy for the College to achieve its long term growth ambitions. John initiated the Imperial White City Campus, leading the College's acquisition of the various land assets and supporting consents for over 4 million sq ft of mixed use development to date. This includes the development of the GradPad Postgraduate student accommodation portfolio; The I-Hub co-location operation in White City; the delivery of 88 Wood Lane and sale and development agreement for Centre House to create a Westmont with a meaningful allocation of apartments for College Key Workers. Most recently John led the Scale Space Joint Venture to expand into digital and FinTech co-location and supported the joint Industrial Strategy with Hammersmith and Fulham. This has created the critical foundations to deliver a genuine and inclusive Academic led White City Innovation District.

  Imperial College

  Chief Investment Officer

  John Anderson

  Chief Investment Officer

  Imperial College

• 

  Mitchell Frizelle

  Mitchell Frizelle is the Laboratory Manager at Engitix Therapeutics, a biotechnology company utilising the unharnessed power of the ECM to accelerate drug discovery.

  Engitix

  Laboratory Manager

  Mitchell Frizelle

  Laboratory Manager

  Engitix

• 

  Colin McCall

  Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs. Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors. Colin is co-head of our Life Sciences Real Estate group.

  Taylor Wessing

  Partner

  Moderator

  Colin McCall

  Partner

  Taylor Wessing

Site Selection And Strategic Design

• 

  Orestis Tzortzoglou

  Orestis Tzortzoglou joined BioMed in 2016 and currently serves as Vice President, Development, UK Market. Orestis has been an integral part of BioMed Realty’s portfolio expansion in the U.K. In response to significant tenant demand in Cambridge, the Company has assembled a pipeline that will deliver up to 1 million square feet of additional Class A space for life science companies. Prior to joining BioMed, Orestis held development roles at London & Regional and Development Securities Plc. Orestis received a Bachelor Degree in Business Administration and Finance from the ATEI University of Athens and a Master of Science Degree from City University of London. He is an RICS Chartered Surveyor.

  BioMed Realty

  Vice President, Development UK

  Orestis Tzortzoglou

  Vice President, Development UK

  BioMed Realty

• 

  Jenny Gardner

  Jenny is a director of development and construction at ARC where she is actively working with the greater ARC team to bring forward millions of square feet of cluster-based development focused on science and innovation. Jenny has spent the majority of her 15-year career focused on commercial life science development; 10 years of that working in America for the largest life science-focused REIT, Alexandria Real Estate, and a further year and a half in the UK as a consultant working for JLL advising developer clients on this niche asset class and its associated commercial opportunities. Jenny is passionate about the life science industry and the role that real estate partnership, both in design and in operation, can play as an enabler for growth at scale as the UK looks to establish itself as a science superpower in the coming decade.

  ARC

  Development & Construction Director

  Jenny Gardner

  Development & Construction Director

  ARC

• 

  Sam Potter

  Design Director

  Reef Group

• 

  Artem Korolev

  Artem Korolev is the Founder and Chief Executive of Mission Street. Over a five-year period, he built the company into one of the UK’s leading specialist investors and developers in science and innovation real estate, with a committed development pipeline in excess of 1m sq ft in Cambridge, Oxford and Bristol. Korolev was previously Head of UK Acquisitions and a member of the founding team of GreenOak Real Estate (now BentallGreenOak). Korolev’s track record spans development, asset management, real estate private equity and finance. This includes property acquisitions and corporate M&A, leading end-to-end delivery of complex development and asset management projects across the UK, and structuring debt and equity financing.

  Mission Street

  Founder and CEO

  Artem Korolev

  Founder and CEO

  Mission Street

• 

  Sally Lee

  Sally Lee, Associate Education & Science Principal, HDR An architect by training, Sally has a reputation for bringing great creativity, innovation and attention to detail to every project she works on, including some of HDR’s most high-profile education, science, workplace, and mixed-use projects around the globe. In her role as Education & Science leader, she directs and executes regional project leadership, strategic planning and business development efforts to help life science corporations and developers achieve their missions and goals.

  HDR

  Associate Education & Science Principal

  Sally Lee

  Associate Education & Science Principal

  HDR

• 

  Richard Walder

  Richard is a Director at Buro Happold and leads their UK Science & Technology Sector work. One of Richard’s current focuses is on helping research organisations to meet net-zero carbon whilst maintaining the flexible facilities that are so important in science. He has led the design of numerous major projects including The Michael Uren Biomedical Engineering Research Hub, The London Institute of Medical Sciences and is currently delivering Europe’s largest multi-let speculative laboratory building.

  Buro Happold

  Science and Technology Sector Director

  Moderator

  Richard Walder

  Science and Technology Sector Director

  Buro Happold

Innovative Spaces: From Incubators To Biomanufacturing Facilities

Presented By Bidwells

• 

  Kathryn Chapman

  Kathryn has recently joined the Babraham Research Campus as Director of Science and Entrepreneurship. A scientist by training, Kathryn’s research career focussed on disease modelling and target discovery at the University of Manchester, Harvard Medical School, Wellcome Trust Sanger Institute and GlaxoSmithKline. Since then, she has established and directed various initiatives which use her passion for creating synergy and impact through academic/business and business/business partnerships. Kathryn established and led the Milner Therapeutics Institute at the University of Cambridge and spent 10 years at the NC3Rs, UKRI working with over 40 pharmaceutical companies in the US and Europe to improve scientific and business processes and reduce animal use in drug development. She has 50+ research publications and sits on a number of national and international Review Panels including for the Innovative Medicines Initiative (IMI), BBSRC and Innovate UK. She holds an honorary Professorship with the University of Coventry where she sits on the Vice-Chancellors Advisory Group for industry/academic engagement. Kathryn works with stakeholders across the Cambridge ecosystem to support cultural change. She is a co-founder of the University of Cambridge’s Connect:Health Tech initiative which includes a thriving online community to connect entrepreneurs across disciplines.

  Babraham Research Campus

  Director of Science & Entrepreneurship

  Kathryn Chapman

  Director of Science & Entrepreneurship

  Babraham Research Campus

• 

  Rob Beacroft

  Director

  Lateral

• 

  Emma Tinsley

  Emma Tinsley is a leading biotech executive and the CEO of Weatherden, a global integrated clinical consultancy and experts in scientific strategy and clinical development. Emma has deep experience of company formation, clinical development strategy, operating model transformation and investment management and was previously at SV Health Investors in the biotech company creation team creating immunology and oncology companies; and prior to this, in the Life Sciences team at KPMG.

  Weatherden

  CEO

  Emma Tinsley

  CEO

  Weatherden

• 

  Emily Slupek

  Emily Slupek is a Partner at Bidwells, with a focus on project management of R&D real estate across the Golden Triangle of Oxford, Cambridge, and London. She excels in delivering complex projects, with expertise in repurposing commercial spaces, labs, offices, and mixed-use developments. Currently, she works on projects at the Harwell Campus and with the University of Oxford. Emily is a recognized figure in the innovation sector, regularly exploring future market trends with speaking slots at conferences and roundtables.

  Bidwells

  Partner

  Emily Slupek

  Partner

  Bidwells

• 

  Oliver Milton

  Oliver is a Partner of Hawkins\Brown and one of the leading architects working in the Science and Technology sector. His experience ranges from state-of-the-art research institutes through to speculative facilities for developers. He thrives on the variety and challenge that the sector offers. Oliver’s contribution to the wider industry includes active membership and participation in several organisations, including as Chair of Designers for Science which promotes best practice and emerging trends in the sector.

  Hawkins Brown

  Partner

  Moderator

  Oliver Milton

  Partner

  Hawkins Brown

• 

  Sue Foxley

  Sue leads a dynamic programme of research, working closely with academics and sector specialists. Much of her work is focused on the real estate implications of the science and technology sector. This includes the Bidwells Life Science 2030 research programme which encompasses a study undertaken in conjunction with YouGov investigating the location drivers of R&D businesses. Sue’s academic background spans the finance, planning and environmental fields. She started her career in academia working on planning and urban design publications at the Center for Urban Policy Research, Rutgers University, USA. She holds an MSc in Property Investment & Finance from Bayes Business School, an MS in Planning and Urban Policy from Rutgers University and a BSc in Rural Environment Studies.

  Bidwells

  Research Director

  Intro Presentation

  Sue Foxley

  Research Director

  Bidwells

Clusters And Collaboration

Presented By Stanhope

• 

  Jonathan Trout

  Jonathan joined Stanhope in 2003 and leads the Property & Commercial aspects of the business, joining the Management team in 2017. He currently heads up a number of Stanhope’s major development projects. Since joining Stanhope, Jonathan has acquired or secured a Development Management role on a number of central London office and mixed use development opportunities. In 2012, he led the acquisition of BBC Television Centre from the BBC for £200m, creating a 2.3m sq ft development opportunity. He is currently working on Television Centre Phase 2 (500 homes), Ruskin Square and a number of other projects. Prior to joining Stanhope, Jonathan qualified as a Chartered Surveyor at Drivers Jonas and worked at Taylor Woodrow in their Central London Mixed use team.

  Stanhope

  Property & Commercial Director

  Jonathan Trout

  Property & Commercial Director

  Stanhope

• 

  Jonathan Pickstone

  Jon has been Strategic Director of Economy at Hammersmith and Fulham Council since 2021 and is also currently a director of the Institute of Economic Development. In Hammersmith and Fulham, he is responsible for a broad remit spanning planning, regeneration, property, housing, and economic development. Notably, Jon’s remit encompasses the borough’s partnership with Imperial College and its pioneering Industrial Strategy, which has enabled the establishment of a world-leading innovation district in White City. Prior to joining Hammersmith and Fulham Council, Jon held a variety of roles across the civil service. He was previously Deputy Director for Regional Economic Development at the Scottish Government, and had before that been Deputy Director for Capital Investment at the Department for International Trade. As Chief Operating Officer of UK Trade & Investment’s Regeneration and Investment Organisation, Jon helped to attract institutional investment into large-scale property and infrastructure developments.

  London Borough of Hammersmith & Fulham

  Strategic Director for Economy

  Jonathan Pickstone

  Strategic Director for Economy

  London Borough of Hammersmith & Fulham

• 

  Dr Suki Balendra

  Suki Balendra a senior leader in the NHS with a 20-year background in facilitating, growing, and promoting health research in the U.K. She has substantial, in-depth experience across sectors including industry, academia, NHS, and central government. She is currently the Life Sciences Lead for the clinical research network in Northwest London. She leads the strategic work with the Life sciences industry in the region. She started her career in the Biotechnology Industry at Abbott Diagnostics Ltd. Within a Good manufacturing practice (GMP) environment she worked on several operational projects to improve efficiency, cost, and reproducibility. She focused her clinical research career within the Diabetes Research Network (DRN) at Imperial College in a national role. The DRN was in the early stages of development when she joined. She was integral to the setup of the network, from creating and establishing new governance structures to working with the charity sector in creating a patient registry to support recruitment of diabetes studies. As the Industry and portfolio lead at the DRN she had direct responsibility for building and maintaining strategic partnerships with life science companies with exceptional success in bringing more research opportunities in diabetes into the U. K. In 2018 she was seconded to the Office of Life Sciences within the Department of Business and Industrial Strategy. where she attracted and negotiated new business to increase the UK’s market share of health and care research activity. During the pandemic she provided operational leadership to the NHS covid vaccine research response in Northwest London. Suki has PhD from the University of Warwick, and she is accredited to black belt in Lean Six Sigma. She is a passionate advocate for UK PLC as the number one destination to conduct clinical trials.

  Imperial NHS

  Life Sciences Lead

  Dr Suki Balendra

  Life Sciences Lead

  Imperial NHS

• 

  Mary Ryan

  Professor

  Imperial College

• 

  David Height

  David is an architect by training, and spent 16 years working at Arup and Arup Associates on a range of masterplans and building design projects. Before joining Arup, he spent 5 years working and studying in Japan, following a Daiwa Foundation Scholarship, working for the design department of Kajima. He reconnected with his Japanese interests when approached by Mitsui Fudosan in 2015, and has been responsible for Mitsui's design and planning input to projects including White City Place, the new extension to the British Library, the second phase of the Television Centre development, the South Molton Street Triangle in Mayfair, and a new office development in Shoreditch in partnership with Edge Technologies. Having worked on a range of life science masterplans for Arup, including the new HQ for Astra Zeneca in Cambridge, GSK in Ulverston, and the University of Cambridge Biocentrum campus, he has continued to pursue the potential for the British Library and White City as new paradigms for life science districts. The Mitsui developments at White City and the British Library are part of a wider international initiative by Mitsui in Tokyo, Boston and San Francisco in life science cluster-forming.

  Mitsui Fudosan UK Ltd.

  Managing Director, Design and Engineering

  David Height

  Managing Director, Design and Engineering

  Mitsui Fudosan UK Ltd.

• 

  Angela Kearns

  Angela Kearns is a Corporate Real Estate partner in Clifford Chance's London office specialising in complex development and urban regeneration projects and their funding, direct and indirect investments and HQ occupiers work. Her work spans a broad range of asset classes including life sciences. Angela was shortlisted for Real Estate Individual (London) of the year at the Legal 500 Awards 2020 and is recognised as a Leading Individual by Legal 500 UK.

  Clifford Chance

  Corporate Real Estate Partner

  Moderator

  Angela Kearns

  Corporate Real Estate Partner

  Clifford Chance

Presentations From

• 

  Kas Mohammed

  Kas Mohammed is the Vice President of the Digital Buildings division at Schneider Electric in the UK and Ireland. His team work within both new and existing buildings across Commercial Real Estate, Healthcare, Life Sciences and Education segments to deliver systems which ensure optimal efficiency and user comfort across all stages of the building life cycle. Kas is passionate about improving sustainability across the built environment and reducing carbon emissions in our sector.

  Schneider Electric

  Vice President, UK&I Digital Buildings

  Delivering Efficient And Sustainable Buildings Through Digitisation

  Kas Mohammed

  Vice President, UK&I Digital Buildings

  Schneider Electric

• 

  Rob Burborough

  Rob Burborough is a partner at 3PM with over 25 years in the science and technology sector. He is a specialist in this sector, and has led projects from all science backgrounds. Rob has collaborated extensively with science park owners in the UK and USA (including Discovery Park, Sandwich; The Oxford Science Park, Oxford; Granta Park, Great Abington; Babraham Institute, Babraham; Biomed, Granta Park, Cambridge; Chesterford Research Park, Saffron Walden). More recently, Rob has been engaged by several organisations to advise at a strategic business case and operational execution level for private companies in respect of the investment opportunities, governance and execution strategies, and ecosystem formation for investment and future growth potential. He has been engaged to act as strategic advisor in support of the operational execution of the growth plans of venture-capital-funded private companies in the pre-revenue commercial science sector as they move from a new-company to a mature business model. Rob has been appointed as expert panel advisor to the ISCF (Industrial Strategy Challenge Fund), focusing on core innovation and energy-efficient buildings, and is considered an industry expert in the project, programme and portfolio management of complex science and technology projects throughout the UK and globally. Rob continues to work very closely with the UK research councils (including UK Research and Innovation, Innovate UK and the Biotechnology and Biological Sciences Research Council).

  3PM

  Partner

  Rob Burborough

  Partner

  3PM